GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Memantine

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Before use: Memantine

Selected IR renal target agrees; this does not validate the full dated mirror or imply equivalence to ER.

Before applying: Use the release-specific maintenance limit and review initial/restart titration.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Memantine - immediate-release tablets

Product / population
Adults with moderate-to-severe Alzheimer-type dementia; exact release formulation.
Renal measure
Cockcroft-Gault creatinine clearance, mL/min.
Before using this finding

Confirm IR, ER or fixed combination; keep the maintenance limit separate from titration and restart instructions.

Renal guidance and important limits

Limits that apply to these rows

These are maintenance limits, not initial titration doses. Do not extrapolate below CrCl 5 or create a dialysis replacement regimen.

Alkaline urine can reduce elimination. Reinitiation after several missed days may require retitration. Fixed memantine/donepezil is a separate product.

Memantine IR - renal maintenance target
Cockcroft-Gault CrCl (mL/min)Source-specific instruction
5-29Target 5 mg twice daily
Mild/moderate renal impairmentNo renal adjustment recommended in selected labeling
Read the retained text before reformatting

Memantine IR - renal maintenance target

Cockcroft-Gault CrCl (mL/min)Source-specific instruction
5-29Target 5 mg twice daily
Mild/moderate renal impairmentNo renal adjustment recommended in selected labeling

These are maintenance limits, not initial titration doses. Do not extrapolate below CrCl 5 or create a dialysis replacement regimen.

Alkaline urine can reduce elimination. Reinitiation after several missed days may require retitration. Fixed memantine/donepezil is a separate product.

Source revision: 09/2021 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af2b73da-1be4-4b7f-929b-acb3b9a10f78

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

Other formulations / related references (2)

Confirm the exact product. These links do not imply interchangeable doses or indications.

Memantine - NAMENDA XR capsulesRelated reference only; not an interchangeable dose or indication.Memantine ER / donepezil - NAMZARIC capsulesRelated reference only; not an interchangeable dose or indication.
All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

Memantine - immediate-release tablets

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Confirm IR, ER or fixed combination; keep the maintenance limit separate from titration and restart instructions.

Adults with moderate-to-severe Alzheimer-type dementia; exact release formulation.

Renal method: Cockcroft-Gault creatinine clearance, mL/min.
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - NAMENDA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Use the release-specific maintenance limit and review initial/restart titration.

Adult immediate-release memantine; not NAMENDA XR.

Renal method: Cockcroft-Gault CrCl, mL/min.
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Before use: Memantine

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source scope and renal guidance

Before use: Memantine

Selected IR renal target agrees; this does not validate the full dated mirror or imply equivalence to ER.

How to use this: Use the release-specific maintenance limit and review initial/restart titration.

Memantine - immediate-release tabletsGlobalRPh RX List - NAMENDA

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeMemantine - immediate-release tabletsGlobalRPh RX List - NAMENDA
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Immediate-release scope. Do not apply this target or titration to extended-release memantine.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/memantine/

Usual Dosing (Adults)

Immediate-release product: begin 5 mg once daily; increase by 5 mg/day no more frequently than weekly to 20 mg/day. Divide total doses above 5 mg/day into two doses.

GRPH-memantine-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal pharmacokinetic comments

The source describes a single-20-mg study: 8 patients with mild impairment (CrCl above 50-80), 8 with moderate impairment (30-49), 7 with severe impairment (5-29 mL/min), and 8 age/weight/sex-matched controls above 80. AUC increased by 4%, 60% and 115%, and elimination half-life by 18%, 41% and 95%, respectively.

GRPH-memantine-02 · Source section: Renal pharmacokinetic commentsRenal section finder

Renal Dosing

No adjustment for mild/moderate impairment. Severe impairment, Cockcroft-Gault CrCl 5-29 mL/min: target 5 mg twice daily.

The source supplies Cockcroft-Gault: male CrCl = (140 - age in years) x weight in kg / (72 x serum creatinine in mg/dL); multiply by 0.85 for females.

GRPH-memantine-03 · Source section: Renal DosingRenal section finder

Hemodialysis

Not recommended in the source.

GRPH-memantine-04 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Memantine - immediate-release tablets

Open original reference

Open / share this exact local source

DailyMed / NLM exact product labeling · Adults with moderate-to-severe Alzheimer-type dementia; exact release formulation.

Renal method: Cockcroft-Gault creatinine clearance, mL/min.
Source date: 09/2021
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Confirm IR, ER or fixed combination; keep the maintenance limit separate from titration and restart instructions.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

These are maintenance limits, not initial titration doses. Do not extrapolate below CrCl 5 or create a dialysis replacement regimen.

Alkaline urine can reduce elimination. Reinitiation after several missed days may require retitration. Fixed memantine/donepezil is a separate product.

Memantine IR - renal maintenance target
Cockcroft-Gault CrCl (mL/min)Source-specific instruction
5-29Target 5 mg twice daily
Mild/moderate renal impairmentNo renal adjustment recommended in selected labeling
Read the retained text before reformatting

Memantine IR - renal maintenance target

Cockcroft-Gault CrCl (mL/min)Source-specific instruction
5-29Target 5 mg twice daily
Mild/moderate renal impairmentNo renal adjustment recommended in selected labeling

These are maintenance limits, not initial titration doses. Do not extrapolate below CrCl 5 or create a dialysis replacement regimen.

Alkaline urine can reduce elimination. Reinitiation after several missed days may require retitration. Fixed memantine/donepezil is a separate product.

RDM64-official-memantine-fe42767bfe-C1 · Source locator: Dosage renal impairment; Clinical Pharmacology; genitourinary/urine-pH and missed-dose instructions.

Source-specific limits

These are maintenance limits, not initial titration doses. Do not extrapolate below CrCl 5 or create a dialysis replacement regimen.

Alkaline urine can reduce elimination. Reinitiation after several missed days may require retitration. Fixed memantine/donepezil is a separate product.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af2b73da-1be4-4b7f-929b-acb3b9a10f78
Retrieved
2026-09-10
Exact label title
Memantine - immediate-release tablets
DailyMed Set ID
af2b73da-1be4-4b7f-929b-acb3b9a10f78
Label revision
09/2021
Renal-function method
Cockcroft-Gault creatinine clearance, mL/min.
Source date/version
09/2021
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
8aa9da188916545d32cc3cfae9bdf5c6d3841f5ff6bcd6dc8ac9643e74f59bcc
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - NAMENDA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult immediate-release memantine; not NAMENDA XR.

Renal method: Cockcroft-Gault CrCl, mL/min.
Source date: November 2018
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Use the release-specific maintenance limit and review initial/restart titration.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

The severe-renal target agrees with the selected IR label. The November 2018 mirror contains encoding damage in its range dash; the dose band is separately legible in official labeling.

Dose escalation is at least one week apart; a prolonged interruption can require lower-dose restart and retitration.

Memantine IR - renal maintenance target
Cockcroft-Gault CrCl (mL/min)Source-specific instruction
5-29Target 5 mg twice daily
Mild/moderate renal impairmentNo renal adjustment recommended in selected labeling
Read the retained text before reformatting

Memantine IR - renal maintenance target

Cockcroft-Gault CrCl (mL/min)Source-specific instruction
5-29Target 5 mg twice daily
Mild/moderate renal impairmentNo renal adjustment recommended in selected labeling

The severe-renal target agrees with the selected IR label. The November 2018 mirror contains encoding damage in its range dash; the dose band is separately legible in official labeling.

Dose escalation is at least one week apart; a prolonged interruption can require lower-dose restart and retitration.

RDM64-rxlist-memantine-911c54e3a3-C1 · Source locator: Dosage and Specific Populations / Renal Impairment.

Source-specific limits

The severe-renal target agrees with the selected IR label. The November 2018 mirror contains encoding damage in its range dash; the dose band is separately legible in official labeling.

Dose escalation is at least one week apart; a prolonged interruption can require lower-dose restart and retitration.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/namenda-drug/
Retrieved
2026-09-10
Renal-function method
Cockcroft-Gault CrCl, mL/min.
Source date/version
November 2018
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
0e140fa4b162d9bc7edce6c0917bbd25d0cac5adee99d360c8a811faf637220c

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/memantine/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
4787ee52ef177ced494c4d8e75abbcad3377fd5ed7439ae378bbcdb03d65f081
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report